Anavex Life Sciences Reports Positive Results from ANAVEX®3-71 Phase 1 Clinical Trial
A phase 1 study of ANAVEX 3-71, an oral small molecule agonist of SIGMAR1 and CHRM1, met its primary safety and secondary endpoint, Anavex Life Sciences recently announced. The drug is in development ...